Navigation Links
Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Date:12/10/2007

-Patients treated with Lovenox(R) (enoxaparin sodium injection) were also

less likely to be readmitted to hospital within 90 days-

BRIDGEWATER, N.J., Dec 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the results of a study that demonstrated total hospital direct medical costs associated with VTE treatment are reduced by $550 per patient when they were treated with the use of low-molecular weight heparin (LMWH) vs. unfractionated heparin (UFH) with 97.3% of LMWH patients receiving Lovenox. Patients who received LMWH were also less likely to be readmitted to the hospital with a VTE recurrence within 90 days. The findings were presented at American Society of Hematology Annual Meeting (ASH) in Atlanta, GA.

The current healthcare and economic burden of venous thromboembolism (VTE) in U.S. hospitals is significant. In patients with confirmed VTE, evidence- based guidelines recommend treatment for a minimum of five days with either a low-molecular weight heparin (LMWH, such as Lovenox) or UFH. However, in the real-world practice, the total hospital direct medical costs and VTE-related readmission rates of these VTE treatment regimens are not clear.

A retrospective real-world cohort study examining discharge and billing records from the Premier Perspective(TM) database included discharges of patients less than 18 years old and with a primary diagnosis of VTE from January 2003 through June 2005. Only VTE patients who were treated with either LMWH or UFH were included in the study. Total hospital direct medical costs associated with VTE treatment (including drug costs, hospital costs, and professional costs) were quantified and compared for patients receiving UFH and LMWH. Furthermore, VTE-related readmission rates at days 30 and 90 post- discharge were compared for both patient cohorts. Total direct medical costs (US $) were compared using multivariate statistics, adjusting for patient and hospital characteristics. Logistic
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 BiologicTx ® today announced ... 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary ... July 9 at the Miami Transplant Institute, located at ... Kidney Paired Donation (KPD) is ... for kidney transplant with one another due to incompatible ...
(Date:7/22/2014)...  A central New York ... Total Artificial Heart implant is home, discharged from ... Freedom® portable driver to wait for a matching ... from a Syracuse architectural hardware company, suffered from ... medications, an implantable defibrillator and a pacemaker. ...
(Date:7/22/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today ... patients in its ongoing Phase 2 trial (Study 202) ... revised clinical protocol agreed to with the FDA in ... proprietary recombinant human hyaluronidase under development for the systemic ... "Our diligent effort to rapidly re-initiate patient enrollment and ...
Breaking Medicine Technology:BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... RIDGEFIELD, Conn., Oct. 24, 2011 Apelon, ... data interoperability solutions, today announced the availability ... solution. TermManager, a code set management and ... interoperability initiatives by enabling widespread access to ...
... Codexis, Inc. (Nasdaq: CDXS ) ... Codex® Screening Kits are in use or evaluation ... worldwide.  The announcement was made at CPhI  Worldwide, ... week.   Codex® Screening Kits were ...
Cached Medicine Technology:Apelon Announces Availability of New TermManager® Software 250 Pharma Companies Worldwide Now Use Codexis In Process Development 2
(Date:7/22/2014)... invasive hysterectomy using electric power morcellation, uterine cancers were ... of the procedure, according to a study published by ... procedure, in which the uterus is fragmented into smaller ... , Despite the commercial availability of electric power morcellators ... malignancy at the time of electric power morcellation (in ...
(Date:7/22/2014)... 2014) -- The American Society of Hematology (ASH) will ... Coulter Award for Lifetime Achievement in Hematology, to Kanti ... Jewish (LIJ) School of Medicine for his 50-year career ... and mentoring, and exceptional patient care. , The ... is bestowed on an individual who has been a ...
(Date:7/22/2014)... may share certain pathogenic mechanisms with cancer, according to ... Linda Kusner, Ph.D. , published in PLOS ... work shows that the very same inhibitors of apoptosis, ... cells that produce autoimmune diseases. Henry Kaminski, M.D. ... GW School of Medicine and Health Sciences (SMHS), as ...
(Date:7/22/2014)... 2014 Ticket Down is a reliable ... at Fedex Field in Landover, MD. There has never been ... of international soccer. After the success of the American national soccer ... alive and well. One way that fans of the world’s sport ... with the 2014 Guinness International Champions Cup. The tournament will kick ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) ... owing to novel medical indications created and due to ... societies where physical appearance is extremely valued. Although the ... competitors, new companies and technologies are setting ground for ... put the price of 1st-gen products under pressure, only ...
Breaking Medicine News(10 mins):Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... possibilities for more accurately determining the composition of ... two techniques that were previously considered to be ... the detection technique mass spectroscopy (MS). He has ... control mechanism for the active ingredient and excipients ...
... Oct. 24 The Certification of Disability,Management Specialists ... Center (UPMC) as the recipient of its 2007 ... programs,to promote the health and productivity of its ... the National Business Group on,Health,s 2007 Joint Forum ...
... LOS ANGELES and LAIYANG, China, Oct. 24 ... Board: GTEC) (to be known as,Genesis Pharmaceutical ... pharmaceutical company in the People,s Republic of ... CCG Elite to design and execute its,investor ...
... While some targeted therapies drugs developed to attack ... cancer cells work well by themselves, increasingly researchers ... other targeted and conventional therapies. , Reported today ... Cancer Therapeutics, multiple-target applications of new and existing drugs ...
... of Cardiovascular Disease Risk, TORONTO, Oct. 24 ... Amex: PME) today announced that clinical data and,preliminary ... the product as,a cost-effective and valuable cardiovascular risk ... the second product in the PREVU(x),line of skin ...
... Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced that ... the U.K. Medicines and Healthcare products Regulatory Agency ... begin a clinical trial using intravenous administration of ... as well as immune modulator, in patients with ...
Cached Medicine News:Health News:New technique improves purity of medicines 2Health News:UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity 2Health News:UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity 3Health News:Genesis Technology Group Retains CCG Elite 2Health News:Genesis Technology Group Retains CCG Elite 3Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product 2Health News:PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product 3
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: